The conversation is about finding genuine sources to buy Pyrilutamide in India and possibly importing it as a group to reduce costs. The user seeks advice on shipping without prescription issues.
The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Users are asked to share their experiences with Pyri/Koshine.
The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.
PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.
A female user with alopecia is researching peptide usage, specifically ghk-cu, for hair loss. Other users shared mixed experiences with copper treatments, noting some success with topical application.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
The post discusses speeding up verteporfin trials for hair loss treatment. The original poster, involved in the trials, requests help in crowdsourcing doctor emails to spread awareness and gather more support for the trials.
Kopexil (Aminexil) is not approved as a drug in the US and Europe because it is marketed as a cosmetic, which requires less testing and regulation. L'Oreal's 1.5% Aminexil is noted to reduce hair shedding, but its efficacy as a drug is not proven.
Stemson Therapeutics announced a breakthrough in hair growth technology using stem cells. Users discussed the potential high cost and skepticism about the treatment's accessibility.
The conversation is about the difficulty of applying both pyril and min/fin to treat hair loss twice daily and whether combining them yields positive results.
The conversation is about finding a legitimate online source for 17α-estradiol (Alfatradiol) powder to make a 0.1% solution for hair loss treatment. A user suggests Anagenica as a source.
The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.
The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.
The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Researching the effectiveness of the hair loss treatment Pyril in comparison to other treatments such as Minoxidil, Finasteride, and RU58841. Replies suggest that users often fail to provide updates on their experience with Pyril.
The conversation discusses using finasteride, dutasteride, minoxidil, cialis, and metformin to protect hair and health. Some users caution against self-prescribing these drugs due to potential risks and complications.
Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.
The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.
Pyrilutamide/KX-826 is being discussed for its effectiveness in hair regrowth, with some users reporting positive results, especially in early hair loss cases. Users have combined it with treatments like Minoxidil, and some experienced initial shedding before seeing regrowth.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references upcoming trial data from Shiseido in Japan.
The conversation is about baricitinib, a medicine that can help with hair loss, and why it isn't more popular or widely discussed. No specific experiences with the treatment were shared.
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
The conversation discusses a botanically derived treatment for androgenetic alopecia using ingredients like saw palmetto, green tea, and evening primrose, showing impressive results over 270 days. Concerns include the study's uncontrolled nature and potential product motivation, with suggestions to enhance absorption through derma rolling.
The conversation discusses creating a topical hair loss treatment by dissolving melatonin in ethanol and possibly mixing it with castor oil, questioning the stability of the solution. An alternative of using glycerin is also considered.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.